The article highlights Johnson & Johnson (NYSE: JNJ) as a top dividend stock for August and September, emphasizing its strong financial performance and appealing dividend growth potential. The company’s fourth-quarter sales increased by 7.3% year-over-year, with earnings rising 39% to $1.70 per share, bolstered by strategic acquisitions like Abiomed. Johnson & Johnson boasts a long history of raising dividends, with a current yield of 3%. Its focus on pharmaceuticals and medical technology, alongside a streamlined business model from a recent spin-off, positions it well for sustained growth, making it a solid investment option despite market fluctuations.